Between 2005 and 2013, the United States prescription drug market grew at an average annual pace of 1.8%. The same market experienced a dramatic growth rate in 2014 of 11.5%.
Between 2005 and 2013, the United States prescription drug market grew at an average annual pace of 1.8%. The same market experienced a dramatic growth rate in 2014 of 11.5%. A new study, published in Health Affairs, sought out to understand if this dramatic increase was a one-time event or a permanent sign of future spending trends.
Murray Aitken, the executive director of the IMS Institute for Healthcare Informatics, in Parsippany, New Jersey, and colleagues found that forecasts suggest a moderation in prescription drug spending growth after 2014. The spending growth will average at 6.7% from 2016 through 2025.
“The recent acceleration in FDA approvals of new drugs, innovative and increasingly patient-friendly formulations, and regulatory initiatives may all be contributing to new treatment options, improved outcomes, and faster drug spending growth,” the authors wrote. “However, consolidation on the demand side by pharmacy benefit managers, insurers’ shift to increased patient copayments, and highly visible drug price increases by some manufacturers suggest that drug spending growth will likely be highly publicized and controversial.”
Study Design and Results
The authors analyzed US prescription drug spending trends using data from IMS Health’s National Sales Perspectives (NSP). Both price and quantity components for brand-name and generic medications were considered.
The observed spending patterns included:
Spending will Increase, but in Moderation
Based on the study of manufacturers’ rebates and discounts on prices, the researchers identified the 3 key factors that will most likely influence prescription spending over the next decade:
The pharmaceutical market landscape is evolving dramatically. However, the sudden growth that was seen in 2014 was a one-time phenomenon. Over the long term, based on the forecasts for 2016 through 2025, the retail prescription drug spending is expected to average at 6.7%.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More